Introduction
lyme disease is a multi-organ disease caused by spirochetes, Borrelia burgdorferi sensu lato, transmitted by Ixodes, with its clinical picture including involvement of the skin, joints, nervous system and heart [1] . Borrelia burgdorferi sensu lato complex includes 18 genospecies of varied pathogenicity. B. burgdorferi sensu stricto, B. garinii, B. afzelii and B. bavariensis are considered in Europe as transparently pathogenic and responsible for the production of clinical signs. However, the presence of Dnas of other potentially pathogenic species, such as B. valaisiana, B. bissettii, B. spielmanii, was revealed in clinical specimens taken from patients with lyme disease symptoms, which proves their importance in the development of clinical manifestation of the infection [2, 3, 4] . B. lusitaniae role in the development of lyme disease remains difficult to determine, given the fact that clinical signs of the infection do not correspond with the known signs of lyme disease.
Early local clinical manifestation of lyme disease includes the presence of an expanding area of redness (erythema migrans, EM), that appears at the site of a tick bite within 3 to 30 days after the bite has occurred, or less frequently the presence of multiple areas of redness (multiple erythema). Erythema can be the only symptom of the developing Borrelia burgdorferi infection, but it can also be concomitant with flu-like symptoms such as fever, headaches, muscle aches and joint pains [2, 5] . Erythema migrans has a diagnostic value and does not require laboratory tests to confirm it, for anti-B. burgdorferi antibodies are not present at that time and negative result of the tests can lead to erroneous diagnosis. anti-B. burgdorferi antibodies appear after 3-4 weeks from the occurrence of EM [6] . other early symptoms of lyme disease include early lyme neuroborreliosis (meningoradiculitis, meningitis, paralysis of the 7th cranial nerve and other cranial nerves), Lyme carditis, Lyme arthritis. Early symptoms of lyme disease are concomitant with the presence in the serum of IgM or IgM/IgG antibodies against specific antigen proteins of B. burgdorferi [2, 5] . If lyme disease is not treated early it may produce late stage changes including lyme neuroborreliosis (encephalomyelitis, radiculoneuritis, meningitis, occlusive vasculitis), Lyme arthritis, synovitis and atrophic inflammation of the skin, usually of the hands and feet (Acrodermatitis chronica athrophicans, ACA). the presence of anti-B. burgdorferi IgG antibodies in the serum accompanies the late stage symptoms of the disease.
Results of serological tests carried out in cases of lyme disease patients with dominating arthralgia and/ or arthritis symptoms, treated symptomatically and with etiotropic antibiotic therapy, indicate the possibility of infection with several species of B. burgdorferi s.l. [9] . Diversity of Borrelia burgdorferi s.l. genospecies must be taken into consideration in the selection of diagnostic tests for patients from a given geographical area, development of new diagnostic tests and diagnostic antigens for serological tests [6] .
two-phase approach in diagnostics of B. burgdorferi s.l. infections, recommended by European Concerted Action on Lyme Borreliosis (EucalB) and Center for Disease Control and Prevention (cDc), has been introduced to limit the occurrence of cross reactions and false positive results [10, 11] . ElISa test is a preliminary test, whereas western-blot (wb) test confirms the specificity of a positive or an uncertainly positive result of ElISa test. wb test cannot be used independently from the first phase of the diagnostic examination [6] . Serological tests determining the level of anti-Borrelia burgdorferi IgM/IgG antibodies cannot be used in the evaluation of treatment effectiveness. Effectiveness of antibiotic therapy should be assessed only on the basis of the dynamics of a clinical picture [1] . anti-B. burgdorferi antibodies can be detected despite proper antibiotic therapy and elimination of clinical signs, and their presence, however, does not prove the continuance of the disease and must be considered in correlation with signs [12] .
Aim of the work
the work aimed at assessing the level of antibodies against specific B. burgdorferi s.l. antigens in persons with suspected lyme disease.
Material and methods
the tested group consisted of 98 patients of the clinic of Infectious Diseases and the clinic and neurological Department of Regional Specialist Hospital in Biala Podlaska with suspected lyme disease. the tested group comprised 60 women aged 17 to 81 years (mean: 56, SD: 14.7) and 38 men aged 16 to 76 years (mean: 52, SD: 15.1). the tested patients usually informed of painful joints (87 patients), while 4 of them had other symptoms such as: bone pains, muscle aches, headaches, numbness. 11 patients informed of symptoms other than joint pains, namely headaches and paresis.
Diagnostics of lyme disease was carried out in accordance with the current standards. During the first phase of the tests, anti-Borrelia burgdorferi IgM/IgG antibodies were marked using ElISa method, and positive the presence of anti-Borrelia burgdorferi... fig. 1) . Figure  2 presents results of diagnostic tests with reference to symptoms reported by patients. 
Discussion
Interpretation of serological test results in persons with suspected lyme disease should be connected with clinical signs observed in patients. It is essential to include information on duration of the disease as being closely connected with the appearance of antibodies against specific antigens. antibodies specific for B. burgdorferi were not detected in 38.8% of tested patients with suspected lyme disease, despite the presence of clinical signs that could have been related to infection with B. burgdorferi. Patients mainly reported joint pains, which may suggest the existence of other than infection with B. burgdorferi causes for the appearance of clinical signs, namely reactive arthritis, infectious arthritis or rheumatoid arthritis [13] .
Recommendations of the 2014 working Group pointed out that "Serological tests are the basis for the laboratory diagnosis of lyme disease. If, however, despite negative laboratory test results, a doctor still suspects, based on clinical signs, late stage lyme disease, he may employ other, additional diagnostic methods, such as detection of spirochete Dna (PcR) or culture. they are also applicable in patients with atypical erythema migrans, with suspected early lyme neuroborreliosis, in which antibodies has not been formed yet, and in patients with decreased immunity" [6] . negative results of serological tests may also be obtained in cases where symptoms of infection are short-term, in acute lyme neuroborreliosis with a short duration of the disease, or in cases where an early antibiotic therapy has been initiated. In such cases, repetition of tests should be considered.
the presence of IgM anti-ospc and anti-p41 is mainly detected in patients with an early manifestation of the disease, whereas lipoprotein ospc is considered in diagnostics of lyme disease as a marker of early B. burgdorferi infection [11] . the presence of antibodies against ospc antigen was detected during own tests in all patients with positive IgM.
Diagnostic importance of ospc decreases in the course of the development of immune response to infection with B. burgdorferi s.l., when there is an increased production of IgG antibodies against many spirochetal protein antigens, including p83/100, p53, p58, p43, p39, p31, p30, p21, Dbpa/p17, p19 [11, 14, 15] . However, Dbpa/p17, p83/100, p39 antigens as well as specific recombinant antigens like VlsE and VlsE c6 peptide are regarded as immunodominant antigens in the late response to B. burgdorferi [6, 16, 17] . Results of the tests confirm the diagnostic importance of p17 and VlsE, for which IgG was detected exceptionally often, in 77% and 74% of cases respectively. the presence of IgG anti-p30 (46%), anti-p39 (44%) and anti-p83 (38%) also indicates their crucial importance in diagnostics of lyme disease.
In patients with a clinical manifestation of joint lyme disease, besides IgG antibodies against VlsE, also IgG against other in vivo antigens, such as BBa36, BBo323, cRaSP3 and pG, were detected [18, 19, 20] . In the lack of IgG antibodies, late stage lyme disease cannot be taken into consideration. the presence of IgM antibodies and the lack of positive results for IgG antibodies do not diagnostically confirm the late stage of the disease [2, 12] . the presence of antibodies themselves, with no signs of infection, is not an indication to initiate treatment [6] .
Conclusions
titres of anti-B. burgdorferi IgM/IgG antibodies obtained in ElISa test, indicating positive or uncertain results in diagnostics of lyme disease, cannot be the only indicant taken into account in making a decision to initiate a treatment. Positive and uncertain results must be confirmed by western-blot test. In diagnostics of lyme disease the co-existence of specific anti-B. burgdorferi antibodies with clinical signs of infection must be taken into consideration.
